Advertisement

Diffuse Type In-Stent Restenosis After Drug-Eluting Stent

15:00 EDT 19th June 2013 | BioPortfolio

Summary

To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.

Description

Despite a significant reduction of angiographic restenosis and the need for repeat revascularization after introduction of DES, post-DES restenosis still occur and the treatment for DES failure is challenging. However, there have been little data for therapeutic strategy for post-DES restenosis, especially diffuse type ISR. Therefore, we need the well-designed randomized trial to achieve the best therapeutic option for the treatment of diffuse type post-DES restenosis.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Conditions

In-Stent Restenosis

Intervention

Sirolimus-eluting stent (cypher, J&J, Cordis), Paclitaxel-eluting stent (Taxus liberte, Boston Scientific)

Location

Soonchunhyang University Bucheon Hospital
Bucheon
Korea, Republic of
138-736

Status

Recruiting

Source

CardioVascular Research Foundation, Korea

Results (where available)

View Results

Links

Medical and Biotech [MESH] Definitions

Drug-eluting Stents

Stents that are covered with materials that are embedded with chemicals that are gradually released into the surrounding milieu.

Neointima

The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.

Ostomy

Surgical construction of an artificial opening (stoma) for external fistulization of a duct or vessel by insertion of a tube with or without a supportive stent.

Endoleak

Postoperative hemorrhage from an endovascular AORTIC ANEURYSM repaired with endoluminal placement of stent grafts (BLOOD VESSEL PROSTHESIS IMPLANTATION). It is associated with pressurization, expansion, and eventual rupture of the aneurysm.

Chromatography, Paper

An analytical technique for resolution of a chemical mixture into its component compounds. Compounds are separated on an adsorbent paper (stationary phase) by their varied degree of solubility/mobility in the eluting solvent (mobile phase).

Clinical Trials [ 1209 Associated Clinical Trials listed on BioPortfolio]

Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions

The purpose of this study is to establish the safety and long-term effectiveness of coronary stenting with the ABT 578-eluting balloon expandable stent (Medtronic, Minneapolis, MN) vs. the...

Non-Acute Coronary occlusIon Treated By Everolimus ELuting Stent

Chronic total coronary occlusions (CTO) have an especially high risk of angiographic restenosis, and need for new revascularization procedures. Drug-eluting coronary stents (DES) have demo...

Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)

The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thromb...

Intra-Individual Comparison of Sirolimus and Paclitaxel Coated Stent (FRE-RACE Study)

The main objective of this study is to assess the safety and effectiveness of the Sirolimus eluting Cypher Select(TM) stent in reducing angiographic in-stent late loss in de novo native co...

Focal In-Stent Restenosis After Drug-Eluting Stent

To evaluate the optimal management of focal in-stent restenosis after drug-eluting stent implantation with sirolimus-eluting implantation versus cutting balloon angioplasty

PubMed Articles [ 2525 Associated PubMed Articles listed on BioPortfolio]

Comparison of edge vascular response after sirolimus- and paclitaxel-eluting stent implantation.

To compare the edges vascular response, we analyzed the intravascular ultrasound (IVUS) parameters after implantation of the sirolimus-eluting stent (SES) or the paclitaxel-eluting stent (PES).

Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients.

Patients on maintenance hemodialysis (HD) are at high risk for restenosis after percutaneous coronary intervention (PCI) even if treated with a sirolimus-eluting stent (SES). The aim of this study was...

Impact of positive peri-stent vascular remodeling after sirolimus-eluting and Paclitaxel-eluting stent implantation on 5-year clinical outcomes.

Background: Positive peri-stent vascular remodeling (PPVR) after drug-eluting stent (DES) implantation is an important mechanism of late-acquired stent malapposition (LASM). Methods and Results: A tot...

New developments in drug-eluting stents.

Although the use of balloon catheters or stents for the treatment of coronary artery lesions shows good short-term results, long-term prognosis due to the occurrence of restenosis in 20%-30% of patien...

Fracture of coronary artery sirolimus eluting stent with formation of four aneurysms.

Coronary stent fracture is a relatively rare but potentially serious complication of coronary artery stenting, in particular with sirolimus-eluting stents. It has been recognized as one possible cause...

More From BioPortfolio on "Diffuse Type In-Stent Restenosis After Drug-Eluting Stent"

Search BioPortfolio: